Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:25 Suppl 1:e12739.
doi: 10.1111/hel.12739.

Review: Gastric cancer: Basic aspects

Carlos Resende  1 , Carla Pereira Gomes  1 , Jose Carlos Machado  1   2
Affiliations
Review

Review: Gastric cancer: Basic aspects

Carlos Resende et al. Helicobacter. 2020 Sep.

Abstract

Gastric cancer is still one of the most prevalent and deadliest cancers in the world. Although our knowledge about the disease has progressed extraordinarily, this has not been accompanied by our capacity to effectively treat the disease. In the last years, immunotherapy made its way into the cancer field and was responsible for major changes in the treatment success rates for several cancer types. Although gastric cancer was not among the first successful targets of this type of therapy, the relationship between this type of cancer, immunosurveillance and immunotherapy is now being actively researched. In this article, we review the literature of the past year regarding the relationship between gastric cancer, its immune microenvironment and response to immunotherapy. Published data indicate that the immune microenvironment influences the clinical behaviour of gastric cancer, and is correlated with its histologic and molecular subtypes with an emphasis on the microsatellite- and EBV-positive tumour subgroups. Although the literature regarding response to immunotherapy is scarce, there is good evidence that patient stratification for immunotherapy is going to become a reality in gastric cancer.

Keywords: EBV; gastric cancer; immunosurveillance; immunotherapy; microsatellite instability; tumor microenvironment.

PubMed Disclaimer

References

REFERENCES

    1. Nishino M, Ramaya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655-668.
    1. Budczies J, Allgäuer M, Litchfield K, et al. Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol. 2019;30:1496-1506.
    1. Fashoyin-Aje L, Donoghue M, Chen H, et al. FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24(1):103-109.
    1. Ji-Hyun K, Shinn-Young K, Eun-Young S, et al. Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. Oncol Lett. 2019;18(3):2661-2669.
    1. Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-375.

LinkOut - more resources